MEDANTA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | MEDANTA | Market Cap | 33,324 Cr. | Current Price | 1,240 ₹ | High / Low | 1,456 ₹ |
| Stock P/E | 67.1 | Book Value | 149 ₹ | Dividend Yield | 0.04 % | ROCE | 17.1 % |
| ROE | 13.2 % | Face Value | 2.00 ₹ | DMA 50 | 1,145 ₹ | DMA 200 | 1,169 ₹ |
| Chg in FII Hold | -0.39 % | Chg in DII Hold | 0.77 % | PAT Qtr | 124 Cr. | PAT Prev Qtr | 107 Cr. |
| RSI | 66.6 | MACD | 39.8 | Volume | 85,338 | Avg Vol 1Wk | 2,32,145 |
| Low price | 955 ₹ | High price | 1,456 ₹ | PEG Ratio | 2.86 | Debt to equity | 0.06 |
| 52w Index | 56.7 % | Qtr Profit Var | -3.54 % | EPS | 18.5 ₹ | Industry PE | 48.6 |
📊 Financials: Medanta shows steady fundamentals with quarterly PAT of ₹124 Cr. versus ₹107 Cr. previously, reflecting moderate profit growth. Debt-to-equity is low at 0.06, ensuring minimal leverage risk. ROE at 13.2% and ROCE at 17.1% are decent but not exceptional compared to industry leaders. Cash flows remain stable, supported by hospital operations and healthcare services.
💹 Valuation: The stock trades at a P/E of 67.1, significantly above the industry average of 48.6, suggesting premium valuation. P/B ratio is ~8.3 (Price ₹1240 / Book Value ₹149), which is high. PEG ratio of 2.86 indicates stretched growth-adjusted valuation. Intrinsic value analysis suggests the stock is overvalued at current levels, with limited upside unless earnings accelerate further.
🏢 Business Model: Medanta operates in the healthcare and hospital sector, focusing on multi-specialty services. Its competitive advantage lies in brand recognition, advanced medical infrastructure, and strong patient trust. The company benefits from rising healthcare demand in India, though margins are sensitive to operating costs and regulatory pressures.
📈 Entry Zone: With DMA 50 at ₹1145 and DMA 200 at ₹1169, the stock is trading above both averages, reflecting strength. RSI at 66.6 indicates near overbought conditions, while MACD at 39.8 confirms bullish momentum. Accumulation near ₹1100–₹1150 would be a more favorable entry zone for long-term investors.
Positive
- 🚀 Strong quarterly PAT growth (₹124 Cr. vs ₹107 Cr.).
- 💰 Low debt-to-equity ratio of 0.06 ensures stability.
- 📈 Rising institutional interest with DII holdings up 0.77%.
- 🌍 Strong brand recognition in healthcare services.
Limitation
- ⚠️ High P/E (67.1) compared to industry average (48.6).
- 📉 PEG ratio of 2.86 suggests stretched valuation.
- 🔄 Dividend yield at 0.04% is negligible for income investors.
Company Negative News
- ⚠️ No major recent negative news, though valuations remain stretched.
Company Positive News
- ✅ Consistent profit growth and operational expansion.
- 📈 Increased DII holdings reflect institutional confidence.
Industry
- 🏥 Healthcare industry benefits from rising demand and demographic trends.
- 📊 Industry P/E at 48.6 reflects optimism and growth potential.
- 🌍 High entry barriers due to infrastructure and regulatory requirements.
Conclusion
Medanta demonstrates solid fundamentals with steady profit growth, low debt, and strong brand equity. However, valuations are stretched on P/E, P/B, and PEG ratios, limiting immediate upside. Entry around ₹1100–₹1150 is favorable, and long-term holding is recommended for investors seeking exposure to India’s growing healthcare sector with stable demand and institutional support.
Would you like me to extend this with a peer comparison against other hospital chains or a technical analysis focusing on chart momentum and support levels?